

Trepadone Selected References

1. Borgonio A, Witte K, Stahrenberg R, Lemmer B. Influence of circadian time, ageing, and hypertension on the urinary excretion of nitric oxide metabolites in rats. *Mech Ageing Dev* 1999 November 2;111(1):23-37.
2. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. *Physiol Rev* 2008;88:1183-1241.
3. Wolosker H, Dumin E, Balan L, Foltyn VN. D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration. *FEBS J* 2008;275:3514-3526.
4. McAlindon TE, Biggee BA. Nutritional factors and osteoarthritis: recent developments. *Curr Opin Rheumatol* 2005 September;17(5):647
5. Cesaro P, Ollat H. Pain and its treatments. *Eur Neurol* 1997;38(3):209-15.
6. Aghabeigi B. The pathophysiology of pain. *Br Dent J* 1992 August 8;173(3):91-7.
7. Zimmermann M. Pathobiology of neuropathic pain. *Eur J Pharmacol* 2001 October 19;429(1-3):23-37.
8. Sawynok J, Reid A. Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. *Behav Brain Res* 1996;73(1-2):63-8.
9. Lewis DA. Anti-inflammatory drugs from plant and marine sources. *Agents Actions Suppl* 1989;27:3-373.
10. Manthey JA. Biological properties of flavonoids pertaining to inflammation. *Microcirculation* 2000;7(6 Pt 2):S29-S34.
11. Friedrich MJ. Loss of nerve: a molecular approach to better treatment of chronic pain. *JAMA* 2000 January 12;283(2):187-8.
12. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. *Curr Atheroscler Rep* 2004;6:461-467.
13. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. *J Am Coll Nutr* 2002;21:495-505.
14. Sawynok J. Adenosine receptor activation and nociception. *Eur J Pharmacol* 1998 April 17;347(1):1-11.
15. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. *Annu Rev Neurosci* 2001;24:31-55.

16. Bach-Rojecky L. Analgesic effect of caffeine and clomipramine: a possible interaction between adenosine and serotonin systems. *Acta Pharm* 2003 March;53(1):33-9.
17. Conlay LA, Zeisel SH. Neurotransmitter precursors and brain function. *Neurosurgery* 1982 April;10(4):524-9.
18. Fernstrom JD. Effects on the diet on brain neurotransmitters. *Metabolism* 1977 February;26(2):207-23.
19. Zeisel SH. Dietary influences on neurotransmission. *Adv Pediatr* 1986;33:23-47.
20. Hochberg MC, Clegg DO. Potential effects of chondroitin sulfate on joint swelling: a GAIT report. *Osteoarthritis Cartilage* 2008;16 Suppl 3:S22-S24.
21. Reginster JY, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. *Rheumatology (Oxford)* 2007;46:731-735.
22. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. *Annu Rev Neurosci* 1991;14:219-45.
23. Willis WD. Role of neurotransmitters in sensitization of pain responses. *Ann N Y Acad Sci* 2001 March;933:142-56.
24. Furst S. Transmitters involved in antinociception in the spinal cord. *Brain Res Bull* 1999 January 15;48(2):129-41.
25. Farber L, Haus U, Spath M, Drechsler S. Physiology and pathophysiology of the 5-HT₃ receptor. *Scand J Rheumatol Suppl* 2004;(119):2-8.
26. Thomas RJ. Excitatory amino acids in health and disease. *J Am Geriatr Soc* 1995 November;43(11):1279-89.
27. Belousov AB, O'Hara BF, Denisova JV. Acetylcholine becomes the major excitatory neurotransmitter in the hypothalamus in vitro in the absence of glutamate excitation. *J Neurosci* 2001 March 15;21(6):2015-27.
28. Dickenson AH, Chapman V, Green GM. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. *Gen Pharmacol* 1997;28:633-638.
29. Ebersberger A. Physiology of meningeal innervation: aspects and consequences of chemosensitivity of meningeal nociceptors. *Microsc Res Tech* 2001 April 15;53(2):138-46.
30. Aley KO, McCarter G, Levine JD. Nitric oxide signaling in pain and nociceptor sensitization in the rat. *J Neurosci* 1998 September 1;18(17):7008-14.

31. Sutherland SP, Cook SP, McCleskey EW. Chemical mediators of pain due to tissue damage and ischemia. *Prog Brain Res* 2000;129:21-38.
32. Ono T, Inoue M, Rashid MH, Sumikawa K, Ueda H. Stimulation of peripheral nociceptor endings by low dose morphine and its signaling mechanism. *Neurochem Int* 2002 December;41(6):399-407.
33. Chevlen E. Opioids: a review. *Curr Pain Headache Rep* 2003 February;7(1):15-23.
34. Herrero JF, Laird JM, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? *Prog Neurobiol* 2000 June;61(2):169-203.
35. Gracely RH. Pain measurement. *Acta Anaesthesiol Scand* 1999 October;43(9):897-908.
36. Ernberg M, Lundeberg T, Kopp S. Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals. *Pain* 2000 March;85(1-2):31-9.
37. Almay BG, Johansson F, Von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. *Pain* 1988 April;33(1):3-9.
38. Abbadie C, Brown JL, Mantyh PW, Basbaum AI. Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. *Neuroscience* 1996 January;70(1):201-9.
39. DeVane CL. Substance P: a new era, a new role. *Pharmacotherapy* 2001 September;21(9):1061-9.
40. Harrison S, Geppetti P. Substance p. *Int J Biochem Cell Biol* 2001 June;33(6):555-76.
41. Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. *Nature* 1997 April 17;386(6626):721-4.
42. Afrah AW, Stiller CO, Olgart L, Brodin E, Gustafsson H. Involvement of spinal N-methyl-D-aspartate receptors in capsaicin-induced in vivo release of substance P in the rat dorsal horn. *Neurosci Lett* 2001 December;316(2):83-6.
43. Pathophysiology or other reference re joint disorders
44. International Symposium on Substance P and Related Peptides: Pain, Inflammation, Visceral and CNS Functions. Proceedings. Shizuoka, Japan, November 3-6, 1992. *Regul Pept* 1993 July 2;46(1-2):1-471.
45. Calder PC, Zurier RB. Polyunsaturated fatty acids and rheumatoid arthritis. *Curr Opin Clin Nutr Metab Care* 2001;4:115-121.

46. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. *Pharmacol Ther* 2006;109:325-338.
47. Wurtman RJ. Dietary treatments that affect brain neurotransmitters. Effects on calorie and nutrient intake. *Ann N Y Acad Sci* 1987;499:179-90.
48. Wurtman RJ, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. *Pharmacol Rev* 1980;32:315-335.
49. Fernstrom JD. Effects of precursors on brain neurotransmitter synthesis and brain functions. *Diabetologia* 1981;20 Suppl:281-289.
50. Fernstrom JD, Fernstrom MH. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. *J Nutr* 2007;137:1539S-1547S.
51. Carlsson A. Interaction between dopaminergic and serotonergic systems. *Clin Neuropharmacol* 1992;15 Suppl 1 Pt A:616A-617A.
52. Dickenson AH. Plasticity: implications for opioid and other pharmacological interventions in specific pain states. *Behav Brain Sci* 1997 September;20(3):392-403.
53. Brown DW. Abnormal fluctuations of acetylcholine and serotonin. *Med Hypotheses* 1993 May;40(5):309-10.
54. Vangsness CT, Jr., Spiker W, Erickson J. A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis. *Arthroscopy* 2009;25:86-94.
55. Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med* 2006;354:795-808.
56. The NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). *J Pain Palliat Care Pharmacother* 2008;22:39-43.
57. Read SJ, Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. *Expert Opin Investig Drugs* 2008;17:619-640.
58. Calder PC. Omega 3 polyunsaturated fatty acids, inflammation and immunity. *World Rev Nutr Diet* 2001;88:109-116.
59. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. *Lipids* 2003;38:343-352.
60. Calder PC. Polyunsaturated fatty acids and inflammation. *Prostaglandins Leukot Essent Fatty Acids* 2006;75:197-202.

61. Sundrarjun T, Komindr S, Archararit N et al. Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis. *J Int Med Res* 2004;32:443-454.
62. Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. *J Rheumatol* 2004;31:1551-1556.
63. Hong H, Xu ZM, Pang BS et al. Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia. *Chin Med Sci J* 2004;19:145-149.
64. Ha E, Zemel MB. Functional properties of whey, whey components, and essential amino acids: mechanisms underlying health benefits for active people (review). *J Nutr Biochem* 2003;14:251-258.
65. Yalcin AS. Emerging therapeutic potential of whey proteins and peptides. *Curr Pharm Des* 2006;12:1637-1643.
66. Teschemacher H. Opioid receptor ligands derived from food proteins. *Curr Pharm Des* 2003;9:1331-1344.
67. Malan TP, Mata HP, Porreca F. Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. *Anesthesiology* 2002 May;96(5):1161-7.
68. Gu Y, Huang LY. Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. *Neurosci Lett* 2002 May 24;324(3):177-80.
69. Aanonsen LM, Wilcox GL. Muscimol, gamma-aminobutyric acidA receptors and excitatory amino acids in the mouse spinal cord. *J Pharmacol Exp Ther* 1989 March;248(3):1034-8.
70. Eide PK, Hole K. Subsensitivity of serotonin and substance P receptors involved in nociception after repeated administration of a serotonin receptor agonist. *J Neural Transm* 1989;77(1):1-10.
71. Costall B, Naylor RJ. 5-HT3 receptors. *Curr Drug Targets CNS Neurol Disord* 2004 February;3(1):27-37.
72. Eide PK, Hole K. Interactions between serotonin and substance P in the spinal regulation of nociception. *Brain Res* 1991 June 7;550(2):225-30.
73. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. *Expert Opin Investig Drugs* 2001 October;10(10):1819-30.
74. Brown DW. Abnormal fluctuations of acetylcholine and serotonin. *Med Hypotheses* 1993;40:309-310.

75. Ulus IH, Wurtman RJ. Choline increases acetylcholine release. *Lancet* 1987;1:624.
76. Fernstrom JD. Dietary precursors and brain neurotransmitter formation. *Annu Rev Med* 1981;32:413-25.
77. Fernstrom JD. Dietary amino acids and brain function. *J Am Diet Assoc* 1994;94:71-77.
78. Berretta N, Paolucci E, Bernardi G, Mercuri NB. Glutamate receptor stimulation induces a persistent rhythmicity of the GABAergic inputs to rat midbrain dopaminergic neurons. *Eur J Neurosci* 2001 September;14(5):777-84.
79. Johnston GA. Medicinal chemistry and molecular pharmacology of GABA(C) receptors. *Curr Top Med Chem* 2002;2:903-913.
80. Ford-Hutchinson AW. Regulation of leukotriene biosynthesis. *Cancer Metastasis Rev* 1994;13:257-267.
81. Cantin AM, Begin R. Glutathione and inflammatory disorders of the lung. *Lung* 1991;169:123-138.
82. Wolosker H. NMDA receptor regulation by D-serine: new findings and perspectives. *Mol Neurobiol* 2007;36:152-164.
83. Ahmadi S, Muth-Selbach U, Lauterbach A, Lipfert P, Neuhuber WL, Zeilhofer HU. Facilitation of spinal NMDA receptor currents by spillover of synaptically released glycine. *Science* 2003 June 27;300(5628):2094-7.
84. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. *Arthritis Res Ther* 2008;10 Suppl 2:S3.
85. Budzinski M, Misterek K, Gumulka W, Dorociak A. Inhibition of inducible nitric oxide synthase in persistent pain. *Life Sci* 2000;66(4):301-5.
86. Holthusen H, Arndt JO. Nitric oxide evokes pain at nociceptors of the paravascular tissue and veins in humans. *J Physiol* 1995 August 15;487 (Pt 1):253-8.
87. Mizutani T, Layon AJ. Clinical applications of nitric oxide. *Chest* 1996 August;110(2):506-24.
88. Hirasawa N, Ohuchi K, Kawarasaki K, Watanabe M, Tsurufuji S. Occurrence of histamine-production-increasing factor in the postanaphylactic phase of allergic inflammation. *Int Arch Allergy Appl Immunol* 1989;88(4):386-93.
89. Galeotti N, Ghelardini C, Bartolini A. Antihistamine antinociception is mediated by Gi-protein activation. *Neuroscience* 2002;109(4):811-8.

90. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. *Prog Neurobiol* 2001;63:637-672.
91. Bugajski J, Gadek-Michalska A, Bugajski AJ. Nitric oxide and prostaglandin systems in the stimulation of hypothalamic-pituitary-adrenal axis by neurotransmitters and neurohormones. *J Physiol Pharmacol* 2004;55:679-703
92. Lauder RM. Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems. *Complement Ther Med* 2009;17:56-62.
93. Dahmer S, Schiller RM. Glucosamine. *Am Fam Physician* 2008;78:471-476.
94. Jacobson KA, Moro S, Manthey JA, West PL, Ji XD. Interactions of flavones and other phytochemicals with adenosine receptors. *Adv Exp Med Biol* 2002;505:163-71.
95. Ribeiro JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. *Prog Neurobiol* 2002 December;68(6):377-92.
96. Luceri C, Caderni G, Sanna A, Dolara P. Red wine and black tea polyphenols modulate the expression of cyclooxygenase-2, inducible nitric oxide synthase and glutathione- related enzymes in azoxymethane-induced f344 rat colon tumors. *J Nutr* 2002 June;132(6):1376-9.
97. Sovak M. Grape Extract, resveratrol, and its analogs: A Review. *J Med Food* 2001;4(2):93-105
98. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *J Nutr* 2000 August;130(8S Suppl):2073S-85S.
99. Jegerschold C, Pawelzik SC, Purhonen P et al. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. *Proc Natl Acad Sci U S A* 2008;105:11110-11115
100. Tsuji-Naito K. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation. *Bioorg Med Chem* 2008;16:9176-9183.
101. Seltzer S, Marcus R, Stoch R. Perspectives in the control of chronic pain by nutritional manipulation. *Pain* 1981 October;11(2):141-8.
102. Fernstrom JD. Can nutrient supplements modify brain function? *Am J Clin Nutr* 2000 June;71(6 Suppl):1669S-75S.
103. Lehnert H, Wurtman RJ. Amino acid control of neurotransmitter synthesis and release: physiological and clinical implications. *Psychother Psychosom* 1993;60(1):18-32.
104. Wurtman RJ. Nutrients affecting brain composition and behavior. *Integr Psychiatry* 1987 December;5(4):226-38.

105. Anderson GH, Johnston JL. Nutrient control of brain neurotransmitter synthesis and function. *Can J Physiol Pharmacol* 1983 March;61(3):271-81.
106. Richardson DC, Schoenherr WD, Zicker SC. Nutritional management of osteoarthritis. *Vet Clin North Am Small Anim Pract* 1997 July;27(4):883
107. Ryan S. Nutrition and the rheumatoid patient. *Br J Nurs* 1995 February 9;4(3):132
108. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. *JAMA* 2000;283:1469-1475.
109. Bell RF. Food and pain: should we be more interested in what our patients eat? *Pain* 2007 May;129(1)
110. Hayward G, Goodwin GM, Cowen PJ, Harmer CJ. Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. *Biol Psychiatry* 2005 March 1;57(5):517-24.
111. Cymet TC. A practical approach to fibromyalgia. *J Natl Med Assoc* 2003 April;95(4):278
112. *Modern Nutrition in Health and Disease*. 10th ed. Philadelphia: Lipincott Williams & Wilkin, 2006.
113. Kris-Etherton PM, Lefevre M, Beecher GR, Gross MD, Keen CL, Etherton TD. Bioactive compounds in nutrition and health-research methodologies for establishing biological function: the antioxidant and anti-inflammatory effects of flavonoids on atherosclerosis. *Annu Rev Nutr* 2004;24:511-38.
114. Buzsaki G, Draguhn A. Neuronal oscillations in cortical networks. *Science* 2004 June 25;304(5679):1926-9.
115. Young SN, Gauthier S. Tryptophan availability and the control of 5-hydroxytryptamine and tryptamine synthesis in human CNS. *Adv Exp Med Biol* 1981;133:221-230.
116. Young SN. Behavioral effects of dietary neurotransmitter precursors: basic and clinical aspects. *Neurosci Biobehav Rev* 1996;20:313-323.
117. Young SN, Gauthier S. Effect of tryptophan administration on tryptophan, 5-hydroxyindoleacetic acid and indoleacetic acid in human lumbar and cisternal cerebrospinal fluid. *J Neurol Neurosurg Psychiatry* 1981;44:323-328.
118. Meyers S. Use of neurotransmitter precursors for treatment of depression. *Altern Med Rev* 2000;5:64-71.
119. Anderson GH, Johnston JL. Nutrient control of brain neurotransmitter synthesis and function. *Can J Physiol Pharmacol* 1983;61:271-281.

120. Fernstrom JD, Fernstrom MH. Monoamines and protein intake: are control mechanisms designed to monitor a threshold intake or a set point? *Nutr Rev* 2001;59:S60-S65.
121. Anderson IM, Mortimore C. 5-HT and human anxiety. Evidence from studies using acute tryptophan depletion. *Adv Exp Med Biol* 1999;467:43-55.
122. Tangphao O, Chalon S, Coulston AM et al. L-arginine and nitric oxide-related compounds in plasma: comparison of normal and arginine-free diets in a 24-h crossover study. *Vasc Med* 1999;4(1):27-32.
123. Fernstrom JD. Effects of the diet and other metabolic phenomena on brain tryptophan uptake and serotonin synthesis. *Adv Exp Med Biol* 1991;294:369-76.
124. Kahkonen S, Ahveninen J, Pennanen S, Liesivuori J, Ilmoniemi RJ, Jaaskelainen IP. Serotonin modulates early cortical auditory processing in healthy subjects: evidence from MEG with acute tryptophan depletion. *Neuropsychopharmacology* 2002 November;27(5):862-8.
125. Pant KC, Rogers QR, Harper AE. Plasma and tissue free amino acid concentrations in rats fed tryptophan-imbalanced diets with or without niacin. *J Nutr* 1974 December;104(12):1584-96.
126. Sahakian BJ, Wurtman RJ, Barr JK, Millington WR, Chiel HJ. Low tryptophan diet decreases brain serotonin and alters response to apomorphine. *Nature* 1979 June 21;279(5715):731-2.
127. Kuksis A, Mookerjea S. Choline. *Nutr Rev* 1978 July;36(7):201-7.
128. Alexander JW. Specific nutrients and the immune response. *Nutrition* 1995 March;11(2 Suppl):229-32.
129. Field CJ, Johnson I, Pratt VC. Glutamine and arginine: immunonutrients for improved health. *Med Sci Sports Exerc* 2000 July;32(7 Suppl):S377-S388.
130. Regulation of serine dehydratase and phosphoglycerate dehydrogenase by proteins and essential amino acids. *Nutr Rev* 1974 March;32(3):88-9.
131. de Koning TJ, Klomp LW. Serine-deficiency syndromes. *Curr Opin Neurol* 2004 April;17(2):197-204.
132. Histidine: An essential amino acid for normal adults. *Nutr Rev* 1975 July;33(7):200-2.
133. Antener I, Verwilghen AM, Van GC, Mauron J. Biochemical study of malnutrition. Part VI: Histidine and its metabolites. *Int J Vitam Nutr Res* 1983;53(2):199-209.
134. Young SN, Teff KL. Tryptophan availability, 5HT synthesis and 5HT function. *Prog Neuropsychopharmacol Biol Psychiatry* 1989;13:373-379.

135. Timiras PS, Hudson DB, Segall PE. Lifetime brain serotonin: regional effects of age and precursor availability. *Neurobiol Aging* 1984;5(3):235-42.
136. Fernstrom JD, Wurtman RJ. Control of brain serotonin levels by the diet. *Adv Biochem Psychopharmacol* 1974;11(0):133-42.
137. Boer J, Duyvendak M, Schuurman FE, Pouw FM, Zaagsma J, Meurs H. Role of L-arginine in the deficiency of nitric oxide and airway hyperreactivity after the allergen-induced early asthmatic reaction in guinea-pigs. *Br J Pharmacol* 1999 November;128(5):1114-20.
138. Cooke JP, Oka RK. Atherogenesis and the arginine hypothesis. *Curr Atheroscler Rep* 2001 May;3(3):252-9.
139. Cerra FB. Nutrient modulation of inflammatory and immune function. *Am J Surg* 1991 February;161(2):230-4.
140. Angel-Meza AR, Ramirez-Cortes L, Adame-Gonzalez IG, Gonzalez B, I, Beas-Zarate C. Cerebral GABA release and GAD activity in protein- and tryptophan- restricted rats during development. *Int J Dev Neurosci* 2002 February;20(1):47-54.
141. Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. *Biomed Pharmacother* 2002;56:215-222.
142. A.P. Simopoulos and L.G. Cleland, Omega-6/Omega-3 Essential Fatty Acid Ratio Vol 92, Karger, Farmington, CT (2003).
143. Fernstrom JD, Fernstrom MH. Diet, monoamine neurotransmitters and appetite control. *Nestle Nutr Workshop Ser Clin Perform Programme* 2001;(5):117-31.
144. Byerley WF, Risch SC. Depression and serotonin metabolism: rationale for neurotransmitter precursor treatment. *J Clin Psychopharmacol* 1985 August;5(4):191-206.
145. Delgado PL, Charney DS, Price LH, Landis H, Heninger GR. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. *Life Sci* 1989;45(24):2323-32.
146. Cocchi R. A syndrome from a possible GABA deficiency. Clinical-therapeutic report on 15 cases. *Acta Psychiatr Belg* 1978 March;78(2):407-24.
147. Efron DT, Barbul A. Modulation of inflammation and immunity by arginine supplements. *Curr Opin Clin Nutr Metab Care* 1998 November;1(6):531-8.
148. Efron DT, Barbul A. Arginine and immunonutrition: a reevaluation. *Nutrition* 2000 January;16(1):73-4.

149. Evoy D, Lieberman MD, Fahey TJ, III, Daly JM. Immunonutrition: the role of arginine. *Nutrition* 1998 July;14(7-8):611-7.
 150. Pita AM, Fernandez-Bustos A, Rodes M et al. Orotic aciduria and plasma urea cycle-related amino acid alterations in short bowel syndrome, evoked by an arginine-free diet. *JPEN J Parenter Enteral Nutr* 2004 September;28(5):315-23.
 151. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K. Serum amino acids in fibrositis/fibromyalgia syndrome. *J Rheumatol Suppl* 1989 November;19:158-63.
 152. Adibi SA, Modesto TA, Morse EL, Amin PM. Amino acid levels in plasma, liver, and skeletal muscle during protein deprivation. *Am J Physiol* 1973 August;225(2):408-14.
 153. Cho ES, Anderson HL, Wixom RL, Hanson KC, Krause GF. Long-term effects of low histidine intake on men. *J Nutr* 1984 February;114(2):369-84.
 154. Pestana A. Dietary and hormonal control of enzymes of amino acid catabolism in liver. *Eur J Biochem* 1969 December;11(2):400-4.
 155. Damas J, Bourdon V, Remacle-Volon G, Lecomte J. Pro-inflammatory flavonoids which are inhibitors of prostaglandin biosynthesis. *Prostaglandins Leukot Med* 1985 July;19(1):11-24.
 156. Lindahl M, Tagesson C. Flavonoids as phospholipase A2 inhibitors: importance of their structure for selective inhibition of group II phospholipase A2. *Inflammation* 1997 June;21(3):347-56.
 157. Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. *Free Radic Biol Med* 2004 August 1;37(3):304-17.
- Rein D, Paglieroni TG, Pearson DA et al. Cocoa and wine polyphenols modulate platelet activation and function. *J Nutr* 2000 August;130(8S Suppl):2120S-6S.